Target family: Complement peptide receptors (type: gpcr)
Target: C3a receptor

Ligand: oryzatensin (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Bioactive peptides derived from natural proteins with respect to diversity of their receptors and physiological effects.
Published in: Peptides

Ligand: oryzatensin (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Designing of an orally active complement C3a agonist peptide with anti-analgesic and anti-amnesic activity.
Published in: Peptides

Ligand: JR14a (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8 pIC50
Reference (Journal): Potent Thiophene Antagonists of Human Complement C3a Receptor with Anti-Inflammatory Activity.
Published in: J Med Chem

Ligand: FLTChaAR (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 6.6 pIC50
Reference (Journal): Selective hexapeptide agonists and antagonists for human complement C3a receptor.
Published in: J Med Chem

Ligand: FLPLAR (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 6.4 pEC50
Reference (Journal): Selective hexapeptide agonists and antagonists for human complement C3a receptor.
Published in: J Med Chem

Ligand: Eu-DTPA-hC3a (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 8.0600004196167 pKd
Reference (Journal): Europium-Labeled Synthetic C3a Protein as a Novel Fluorescent Probe for Human Complement C3a Receptor.
Published in: Bioconjug Chem

Ligand: E7 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 8.699999809265137 pEC50
Reference (Journal): Selective hexapeptide agonists and antagonists for human complement C3a receptor.
Published in: J Med Chem

Ligand: E7 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 8.699999809265137 pEC50
Reference (Journal): Evidence that the receptor for C4a is distinct from the C3a receptor.
Published in: Immunopharmacology

Ligand: E7 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 8.699999809265137 pEC50
Reference (Journal): Designing synthetic superagonists of C3a anaphylatoxin.
Published in: Biochemistry

Ligand: compound 4 [PMID: 25259874] (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 5.889999866485596 pIC50
Reference (Journal): Potent heterocyclic ligands for human complement c3a receptor.
Published in: J Med Chem

Ligand: compound 21 [PMID: 25259874] (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 7.699999809265137 pEC50
Reference (Journal): Potent heterocyclic ligands for human complement c3a receptor.
Published in: J Med Chem

Ligand: compound 17 [PMID: 24257095] (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 8.100000381469727 pEC50
Reference (Journal): Downsizing a human inflammatory protein to a small molecule with equal potency and functionality.
Published in: Nat Commun

Ligand: casoxin C (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 4.400000095367432 pIC50
Reference (Journal): Bioactive peptides derived from natural proteins with respect to diversity of their receptors and physiological effects.
Published in: Peptides

Ligand: casoxin C (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 4.400000095367432 pIC50
Reference (Journal): Identification of casoxin C, an ileum-contracting peptide derived from bovine kappa-casein, as an agonist for C3a receptors.
Published in: Peptides

Ligand: C3a receptor agonist (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 6.099999904632568 pIC50
Reference (Journal): Discovery of new C3aR ligands. Part 2: amino-piperidine derivatives.
Published in: Bioorg Med Chem Lett

Ligand: C3a (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 9.619999885559082 pEC50
Reference (Journal): Evidence that the receptor for C4a is distinct from the C3a receptor.
Published in: Immunopharmacology

Ligand: C3a (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 7.3 pEC50
Reference (Journal): Selective hexapeptide agonists and antagonists for human complement C3a receptor.
Published in: J Med Chem

Ligand: albutensin A (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Albutensin A and complement C3a decrease food intake in mice.
Published in: Peptides

Ligand: albutensin A (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Bioactive peptides derived from natural proteins with respect to diversity of their receptors and physiological effects.
Published in: Peptides

Ligand: Ac-RHYPLWR (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 5.960000038146973 pEC50
Reference (Journal): Derivation of ligands for the complement C3a receptor from the C-terminus of C5a.
Published in: Eur J Pharmacol